Double-blind, Randomised, Placebo-controlled, Phase IIb Trial on the Efficacy and Safety of Norursodeoxycholic Acid Tablets in Patients With Non-alcoholic Steatohepatitis (NASH)
Latest Information Update: 29 Sep 2024
Price :
$35 *
At a glance
- Drugs Norursodeoxycholic acid (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Therapeutic Use
- Sponsors Dr Falk Pharma
- 31 Aug 2024 This trial has been completed in Czechia according to European Clinical Trials Database record.
- 10 Aug 2024 This trial has been completed in Belgium.
- 15 Feb 2023 Planned End Date changed from 1 Apr 2022 to 1 Apr 2025.